Caitlin Raymond: The Unmeasured Risks of Consecutive Daily TPE
Caitlin Raymond, Assistant Professor of Pathology and Transfusion Medicine at University of Wisconsin-Madison, shared a post on LinkedIn about her recent article, published in Transfusion, adding:
“My letter to the editor was just published in Transfusion, responding to a study on consecutive daily therapeutic plasma exchange (TPE) using albumin-only replacement fluid.
The original paper found serious bleeding is rare in well-screened patients – a solid and useful finding.
But two things weren’t addressed, and I think they matter:
- Efficacy was assumed, not measured. TPE clears the intravascular space, but substances like IgG take up to 48 hours to re-equilibrate from extravascular tissue. Daily procedures may be hitting the same pool repeatedly before that re-equilibration happens – which could mean less total antibody removed, not more efficient removal.
- Drug removal wasn’t measured either. Most outpatients in the study were kidney transplant patients on calcineurin inhibitors. No drug levels were checked, and the safety window was capped at 72 hours – too short to catch effects on graft outcomes that might play out over months.
Efficient doesn’t automatically mean equally effective. Before consecutive daily TPE becomes standard outside crisis settings, I think we owe patients and their teams direct data on both fronts.”
Title: Beyond bleeding: Unstudied questions of efficacy and drug removal in consecutive daily therapeutic plasma exchange
Author: Caitlin Raymond
Other posts featuring Caitlin Raymond on Hemostasis Today.
-
Oct 20, 2026, 06:45Grant Garcia: Why Does a Blood Clot Diagnosis Immediately End an Athlete’s Season?
-
Oct 20, 2026, 06:35Parag Tamhankar: Landmark Study Reveals Genetic Spectrum and Targeted Therapies for ALPS in the Indian Population
-
Oct 20, 2026, 06:26Nina Houben: Neonatal Blood Transfusion Symposium and PhD Defense
-
Oct 20, 2026, 05:46Jan T. Kielstein: DNP Poisoning and Hemoadsorption The Limits of Rescue Therapy
-
Oct 20, 2026, 05:33Giulia Di Paolo: Connecting Plasma Donation to the Patients Who Depend on It
-
Oct 20, 2026, 05:20James Knowles: Exploring Plasma Manufacturing and Strengthening Industry Collaboration
-
Oct 20, 2026, 05:11Giuseppe Lippi։ Understanding Liver Test Abnormalities After AAV Gene Therapy
-
Oct 20, 2026, 05:02Sanam Loghavi: Test Your Hematology Knowledge at ASH 2026!
-
Oct 20, 2026, 04:13Ifeanyichukwu Ifechidere: DOACs Are Not the Answer to Every Anticoagulation Question